These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Adjuvant mitotane in adrenocortical carcinoma. Machens A; Dralle H N Engl J Med; 2007 Sep; 357(12):1258-9; author reply 1259. PubMed ID: 17891837 [No Abstract] [Full Text] [Related]
6. Adjuvant mitotane in adrenocortical carcinoma. Bertherat J; Coste J; Bertagna X N Engl J Med; 2007 Sep; 357(12):1256-7; author reply 1259. PubMed ID: 17881760 [No Abstract] [Full Text] [Related]
7. Adjuvant mitotane in adrenocortical carcinoma. Dickstein G; Shechner C; Nativ O N Engl J Med; 2007 Sep; 357(12):1257-8; author reply 1259. PubMed ID: 17891838 [No Abstract] [Full Text] [Related]
8. Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection. Terzolo M; Baudin AE; Ardito A; Kroiss M; Leboulleux S; Daffara F; Perotti P; Feelders RA; deVries JH; Zaggia B; De Francia S; Volante M; Haak HR; Allolio B; Al Ghuzlan A; Fassnacht M; Berruti A Eur J Endocrinol; 2013 Sep; 169(3):263-70. PubMed ID: 23704714 [TBL] [Abstract][Full Text] [Related]
9. [Mitotane in the treatment of adrenal carcinoma]. Sane T Duodecim; 2010; 126(17):2040-6. PubMed ID: 21053521 [TBL] [Abstract][Full Text] [Related]
10. Adjuvant mitotane in adrenocortical carcinoma. Lee JE N Engl J Med; 2007 Sep; 357(12):1258; author reply 1259. PubMed ID: 17891836 [No Abstract] [Full Text] [Related]
11. Outcomes of Adjuvant Mitotane after Resection of Adrenocortical Carcinoma: A 13-Institution Study by the US Adrenocortical Carcinoma Group. Postlewait LM; Ethun CG; Tran TB; Prescott JD; Pawlik TM; Wang TS; Glenn J; Hatzaras I; Shenoy R; Phay JE; Keplinger K; Fields RC; Jin LX; Weber SM; Salem A; Sicklick JK; Gad S; Yopp AC; Mansour JC; Duh QY; Seiser N; Solorzano CC; Kiernan CM; Votanopoulos KI; Levine EA; Staley CA; Poultsides GA; Maithel SK J Am Coll Surg; 2016 Apr; 222(4):480-90. PubMed ID: 26775162 [TBL] [Abstract][Full Text] [Related]
12. Adjuvant mitotane therapy of adrenal cancer - use and controversy. Schteingart DE N Engl J Med; 2007 Jun; 356(23):2415-8. PubMed ID: 17554125 [No Abstract] [Full Text] [Related]
13. Mitotane Monotherapy in Patients With Advanced Adrenocortical Carcinoma. Megerle F; Herrmann W; Schloetelburg W; Ronchi CL; Pulzer A; Quinkler M; Beuschlein F; Hahner S; Kroiss M; Fassnacht M; J Clin Endocrinol Metab; 2018 Apr; 103(4):1686-1695. PubMed ID: 29452402 [TBL] [Abstract][Full Text] [Related]
14. Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers. Fassnacht M; Johanssen S; Fenske W; Weismann D; Agha A; Beuschlein F; Führer D; Jurowich C; Quinkler M; Petersenn S; Spahn M; Hahner S; Allolio B; J Clin Endocrinol Metab; 2010 Nov; 95(11):4925-32. PubMed ID: 20668036 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma. Fassnacht M; Hahner S; Polat B; Koschker AC; Kenn W; Flentje M; Allolio B J Clin Endocrinol Metab; 2006 Nov; 91(11):4501-4. PubMed ID: 16895957 [TBL] [Abstract][Full Text] [Related]
16. [Normalisation of contralateral adrenal function after long-term mitotane therapy in a girl after surgical treatment of adrenocortical carcinoma]. Lecka A; Ginalska-Malinowska M Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(3):234-6. PubMed ID: 17020662 [TBL] [Abstract][Full Text] [Related]
17. The long-term survival in adrenocortical carcinoma with active surgical management and use of monitored mitotane. Wängberg B; Khorram-Manesh A; Jansson S; Nilsson B; Nilsson O; Jakobsson CE; Lindstedt S; Odén A; Ahlman H Endocr Relat Cancer; 2010 Mar; 17(1):265-72. PubMed ID: 20026647 [TBL] [Abstract][Full Text] [Related]